Tildren® is indicated for the control of clinical signs associated with navicular syndrome in horses.
Navicular syndrome is the most common cause of chronic forelimb lameness in performance horses. It is a degenerative process instigated by mechanical forces.
- Restores balance to the process of bone remodeling
- Decrease mineral loss and slow the rate of bone turnover
- Alleviate pain induced by abnormal osteolysis
Tildren® restores balance to the process of bone remodeling.
Tildren® partially inhibits bone resorption by:
- Inhibiting osteoclastic activity (Destroys excess osteoclasts)
- Not modifying osteoblastic activity (Bone formation remains the same)
- Slowing the rate of bone turnover (Bone resorption is slowed, but not stopped)
Tildren® mode of action:
1 Inhibition of osteoclast pump
2 Disruption of the osteoclast cytoskeleton
3 Creation of a cytotoxin
- Tildren®-related clinical signs of colic are well characterized and self-limiting
- Do not use NSAIDs concurrently with Tildren®
- Concurrent use may increase the risk of renal toxicity and acute renal failure
- Horses should be well hydrated prior to administration
- Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol.
- Do not use in horses with impaired renal function or with a history of renal disease.
- Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions.
- The safe use of Tildren® has not been evaluated in horses less than 4 years of age.
- Bisphosphonates should not be used in pregnant or lactating mares, or mares intended for breeding.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Always consult with your veterinarian if you suspect your horse may have navicular syndrome as the clinical signs can vary.
Tildren® is a registered trademark of Ceva Santé Animale, S.A.